Category - Feature

Feature

S1 Biopharma to start Phase 2b study in female HSDD by yearend

By Len Zehr Closely-held S1 Biopharma expects to initiate a Phase 2b study at the end of the year with its lead product candidate for female hypoactive sexual desire disorder (HSDD), Lorexys, and a Phase 2a program with...

June 14, 2016

Feature

ESSA Pharma takes unique approach to prostate cancer

By Len Zehr A marine sponge, Geodia lindgreni, native to Papua New Guinea may hold the key to a new approach in the treatment of prostrate cancer by ESSA Pharma (NASDAQ:EPIX; TSX:EPI). “Our scientific founders from the...

June 7, 2016

Feature

Lipocine advancing pipeline, PDUFA for oral TRT

By Len Zehr With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing...

May 31, 2016

Feature

Delivra implementing U.S. expansion strategy for topical creams

By Len Zehr The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through...

May 24, 2016

Feature

ARIAD hopes to launch second oncology drug in early 2017

By Len Zehr ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small...

May 17, 2016

Feature

Profound Medical readies pivotal clinical trial of TULSA-PRO

By Len Zehr After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX...

May 3, 2016

Feature

In conversation with Paul Gunn

By Len Zehr As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by...

April 26, 2016

Feature

Xagenic readies X1 molecular diagnostic beta trials

Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in...

April 19, 2016

Feature

In conversation with Jerry Ropelato

By Len Zehr As CEO and founder of closely-held WhiteClouds, which operates the largest 3D color printing facility in the world, Jerry Ropelato is passionate about using the technology to create stunning models for the...

April 12, 2016

Feature

Microbix validating new virology production process

By Len Zehr Microbix Biosystems (TSX:MBX) is validating a new bioreactor manufacturing platform for its world-leading line of viral and bacterial antigens and other virology products ahead of a full roll-out to...

April 5, 2016

Category - Feature

S1 Biopharma to start Phase 2b study in female HSDD by yearend

ESSA Pharma takes unique approach to prostate cancer

Lipocine advancing pipeline, PDUFA for oral TRT

Delivra implementing U.S. expansion strategy for topical creams

ARIAD hopes to launch second oncology drug in early 2017

Profound Medical readies pivotal clinical trial of TULSA-PRO

In conversation with Paul Gunn

Xagenic readies X1 molecular diagnostic beta trials

In conversation with Jerry Ropelato

Microbix validating new virology production process

General

More